Edition:
United States

Starpharma Holdings Ltd (SPL.AX)

SPL.AX on Australia Stock Exchange

0.79AUD
25 Jul 2017
Change (% chg)

-- (--)
Prev Close
$0.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
231,743
52-wk High
$0.88
52-wk Low
$0.59

Latest Key Developments (Source: Significant Developments)

Starpharma Holdings says vivagel® condom has been launched in Canada by Ansell
Tuesday, 11 Apr 2017 09:05pm EDT 

Starpharma Holdings Ltd :Vivagel® condom has been launched in Canada by Ansell under lifestyles® dual protect™ brand.  Full Article

Starpharma Holdings says vivagel® condom has been launched in Canada by Ansell
Tuesday, 11 Apr 2017 07:03pm EDT 

Starpharma Holdings Ltd :Vivagel® condom has been launched in Canada by Ansell under lifestyles® dual protect™ brand.  Full Article

Starpharma complates Vivagel BV phase 3 trials
Wednesday, 29 Mar 2017 09:03pm EDT 

Starpharma Holdings Ltd : Vivagel BV phase 3 trials for prevention of BV completed . Starpharma expects topline results of trials to be available in Q2 of 2017 .Has been granted a special protocol agreement by FDA which provides company with binding FDA agreement on trial design including primary endpoint.  Full Article

Starpharma complates Vivagel BV phase 3 trials
Wednesday, 29 Mar 2017 06:40pm EDT 

Starpharma Holdings Ltd : Vivagel BV phase 3 trials for prevention of BV completed . Starpharma expects topline results of trials to be available in Q2 of 2017 .Has been granted a special protocol agreement by FDA which provides company with binding FDA agreement on trial design including primary endpoint.  Full Article

Starpharma says it was granted qualified infectious disease product and fast track designation for vivagel by FDA
Wednesday, 11 Jan 2017 05:21pm EST 

Starpharma Holdings Ltd :granted qualified infectious disease product (qidp) and fast track designation for vivagel® bv by US Food and Drug Administration (FDA)..  Full Article

Starpharma signs exclusive license and supply agreement in China
Wednesday, 20 Jul 2016 11:10pm EDT 

Starpharma Holdings Ltd : Signs exclusive license and supply agreement with Shenyang sky and land latex for manufacture and sale of vivagel condoms .  Full Article

Starpharma Holdings licences VivaGel BV to Aspen for ANZ
Thursday, 3 Mar 2016 06:41pm EST 

Starpharma Holdings Ltd:Starpharma licences vivagel bv to Aspen for anz.Says signing of a license and supply agreement with Aspen Pharmacare Australia pty ltd.Says agreemnt for the sales and marketing of vivagel bv in Australia and New Zealand (anz).Says commercial terms of the agreement remain confidential.  Full Article

Starpharma signs mou for Vivagel Condom in China
Tuesday, 15 Dec 2015 04:45pm EST 

Starpharma:Starpharma signs mou for Vivagel Condom in China.Says signed a memorandum of understanding (mou) with a Chinese company who is a major provider of condoms to the Chinese government.Says Starpharma will work with its partner to proceed with the regulatory process in preparation for market launch.  Full Article

Starpharma Holdings announces EU marketing approval granted for Vivagel BV
Wednesday, 23 Sep 2015 08:09pm EDT 

Starpharma Holdings Ltd:EU marketing approval granted for Vivagel BV.Says approval for the treatment and rapid relief of Bacterial Vaginosis (BV) including symptoms.Says the approval allows for the marketing of Vivagel BV in the European economic area.Says discussions regarding marketing rights for Vivagel BV are already underway.EU approval will be used as basis for obtaining rapid regulatory and marketing approvals in other countries that recognise EU approval.  Full Article

Starpharma signs drug delivery license with AstraZeneca
Monday, 7 Sep 2015 01:40am EDT 

Starpharma Holdings Ltd:Says it has signed a licensing agreement with Starpharma for the use of its DEP ( (reg) ) drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound on signature, and with potential for follow on compounds directed at a defined family of targets.Says under the agreement it will receive a signature payment of $2 million (A$2.9 million), and is also eligible to receive potential development, launch and sales milestones for the first AstraZeneca DEP ( (reg) ) product of $124 million (A$177 million).  Full Article